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ABSTRACT 
 
Epigenetic patterns established during early bovine embryogenesis via DNA 
methylation and histone modification patterns are essential for proper gene expression and 
embryonic development. Epigenome patterns established during this period, if improperly 
maintained, can lead to developmental anomalies and may partially explain the lower 
pregnancy rates of in vitro-produced embryos. We hypothesized that the histone 
methyltransferase of ASH2L would alter preimplantation development, epigenetic 
reprogramming, and gene expression profiles in the early bovine embryo. We observed that 
the depleted and deleted ASH2L embryos developed to the blastocyst stage with suppressed 
ASH2L having comparable development rates with its respective control (31.3 ± 2.0%, 
n = 466 v. 34.8 ± 1.9%, n = 418). To see if errors were in the chromatin structure at the 
blastocyst stage, DNA methylation and histone modifications were examined to further 
explain the role of ASH2L during embryonic development. Blastocysts from each treatment 
(N = 601) were fixed and prepared for immunocytochemistry following standard laboratory 
protocol. Our findings show ASH2L may play a role in DNA methylation by decreasing 5mc 
and 5hmc conversion, which is a key event during early embryonic development. 
Suppression of ASH2L also alters global levels of H3H4me3 and H3K27me3 (p<0.001), 
which may lead to transcription aberrations. RNA-seq showed altered gene expression 
profiles in 407 genes in the morphologically comparable Day 17 conceptus (p<0.05). Closer 
examination showed that there is altered mesenchymal stem cell differentiation present in the 
Day 17 conceptuses. Analysis of ASH2L shows to not have a detrimental effect during 
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preimplantation development but altered chromatin status and gene expression profiles 
suggest that ASH2L could play a vital role later in development.   
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NOMENCLATURE 
 
5hmc   5-hydoxymethylcystosine 
5mc   5-methylcytosine 
Amp   Ampicillin  
ARTs   Assisted reproductive technologies 
AS   Angelman Syndrome 
bp   Base pairs 
BWS   Beckwith-Wiedemann Syndrome 
cDNA   Complementary DNA 
ChIP   Chromatin histone immunoprecipitation 
CIDR   Controlled internal drug release 
CL   Corpus luteum  
CpG   Cytosine-Guanine (dinucleotides) 
CRISPR  Clustered regularly-interspaced short palindromic repeats 
DNMTs  DNA methyltransferases 
dsRNA  Double-stranded RNA 
FBS   Fetal bovine serum 
H3K4   Histone 3 Lysine 4 
H3K9   Histone 3 Lysine 9 
H3K27  Histone 3 Lysine 27 
HMTs    Histone methyltransferases 
HOX   Homeobox  
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ICC   Immunocytochemistry 
IFNT   Interferon tau 
InDels   Insertion or deletions 
IVC   In vitro culture 
IVF   In vitro fertilization 
IVM   In vitro maturation 
IVP   In vitro produced 
IVT   In vitro transcription 
NHEJ   Nonhomologous end joining 
LOS   Large offspring syndrome 
MDBK  Madin-Darby bovine kidney  
me2   Dimethylation 
me3   Trimethylation  
MLL   Mixed Lineage Leukemia 
mRNA   Messenger RNA 
PAM   Protospacer adjacent motif 
PcG   Polycomb group 
PCR   Polymerase chain reaction 
PHD   Plant homeodomain 
Puro   Puromycin  
RISC   RNA induced silencing complex 
RNAi   RNA interference 
RT-qPCR  Real-time quantitative PCR 
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SCNT   Somatic cell nuclear transfer 
Seq   Sequencing 
siRNA   small interfering RNA 
sgRNA  small guide RNA  
SPRY   SPIa/RYanodine receptor 
TrxG   Trithorax Group 
TSS   Transcription start sites 
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CHAPTER I 
INTRODUCTION 
 
Assisted Reproductive Technologies in Cattle and Humans 
With the introduction of the first in vitro produced bovine calf in 1981, in vitro 
fertilization (IVF) has become an increasingly utilized technique within the bovine embryo 
transfer industry [1]. Assisted reproductive technologies (ARTs) that produce embryos 
outside of the in vivo environment include in vitro maturation (IVM), IVF, and in vitro 
culture (IVC). When these technologies are combined the embryos are often refered to as in 
vitro produced (IVP).  IVP is a useful method that producers can incorporate into their 
business to increase offspring from superior cattle at a faster rate when compared to in vivo 
production. The attraction to this technique is demonstrated by the reported 443,533 bovine 
IVP embryos in 2013 (IETS Statistics, 2013). When compared to five years earlier, there is a 
substantial increase as only 245,260 embryos were reported from IVP techniques (IETS 
Statistic, 2008). Over this period, there was also an increased proportion of IVP embryos 
being transferred into recipients (38.8% vs 29.7%; IETS Statistics, 2013 & 2008 
respectively).  
As in vitro technologies began to be commercialized, these IVP embryos resulted in 
inferior pregnancy rates (56% fresh and 42% frozen) when compared to their in vivo 
counterparts derived from superovulation and embryo transfer (76% fresh and 64% frozen) 
[2]. In a more recent examination of the industry, lower pregnancy rates were still present on 
Day 30 (32% vs 46%) and Day 60 (27% vs 42%) [3]. Additional studies support this 
decrease in pregnancy on Day 60 when comparing the in vitro and in vivo produced embryos 
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(33.5% verse 41.2%, respectively) [4]. These decreased pregnancy rates suggest IVP 
embryos are developmentally inferior and improvements are necessary in culture systems in 
order to optimize embryo quality and pregnancy rates [5].   
 Altered development rates were further highlighted with the increase use of somatic-
cell nuclear transfer (SCNT) in cattle. It was shown that cloned fetuses had increased 
abortion rates during pregnancy, with viability being reported as low as 10% on Day 180 [6]. 
Failure in normal placentation was found to be the major cause of this failure in pregnancy 
[7]. The small percent of fetuses from SCNT survived through gestation sometimes exhibited 
phenotypic anomalies at birth. It was observed that cloned fetuses resulted in an approximate 
20% increase in birth weight when compared to calves from embryo transfer and artificial 
insemination. This phenomenon became commonly known as large offspring syndrome 
(LOS). LOS calves also presented multiple health issues that were believed to be caused by 
cloning techniques and in vitro culture conditions [8, 9]. These abnormal calves from SCNT 
were also found to have abnormal gene expression patterns of developmentally important 
genes that lead to the altered physiological and phenotypic variation from the in vivo 
offspring [10, 11]. These findings in bovine provide insight for other species, including 
humans, that have similar phenotypic anomalies in offspring associated with ARTs.  
In humans, there is increase use of ARTs since the first IVF baby born in 1978. In 
2013, more than 1.5% (63,286) of children were reported to be born in the United States 
from these techniques. However, there were also numerous failed instances of producing a 
viable offspring from ARTs, with a reported 111,676 (63.8%) attempts being unsuccessful 
(2013 Fertility Clinic Report, CDC). With the average age of the human reproductive 
population increasing, there is a projected decrease in fertility.  This suggests ARTs will be a 
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more commonly used technique in the future [12]. With the reported large number of failed 
IVF attempts in humans, it suggests errors are present in gene expression patterns of these 
early embryos [13, 14]. Similar to observations of LOS in cattle and sheep; ARTs in humans 
have also been linked to imprinting disorders Beckwith-Wiedemann Syndrome (BWS) and 
Angelman Syndrome (AS) [15, 16]. Children born with BWS are reported to be overweight 
and have atypical phenotypes present at birth. Children with BWS are also more prevalent to 
tumorigenesis and other health risks throughout life [17]. With the mounting evidence of 
epigenetic errors present in these offspring, it is important to investigate factors present 
during in vitro culture that cause abnormal embryonic development [18].  
These findings from ARTs in both humans and cattle offspring have led researchers 
to take a closer look at gene expression profiles of IVP embryos and the subsequent offspring 
[19]. It has been shown in mice that abnormal regulation of genomic imprinting regions were 
present due to different in vitro culture mediums being utilized [20]. Epigenetic disruption to 
imprinted genes has previously been identified as a potential mechanism that leads to the 
abnormal placentation, and thus, phenotypic difference for LOS, BWS, and AS. Further 
investigation of IVP embryos in cattle discovered a large proportion of embryos exhibited 
errors in  gene expression profiles when compared to in vivo produced embryos [21]. Later 
studies used deep transcriptome analysis further validated these differenes in gene expression 
between the in vitro and in vivo produced embryos. These anomalies associated with ARTs 
shows a need for better culture systems in order to facilitate fertilization without the 
detrimental side effects.  
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Epigenetics 
Epigenetics means “above genetics” and refers to DNA methylation and/or histone 
modifications that regulate transcription [22]. These modifications do not alter the underlying 
DNA sequence, but instead influence transcription by alterations in chromatin structure. It 
was believed for the majority of the twentieth century that genetics, environment, and 
developmental biology were entirely separate fields [23]. It was not until the 1960s, the 
science of epigenetics established a link between these fields [24]. Due in part to technical 
advances in analysis of chromatin components, a vast amount of research has been 
accomplished to characterize epigenetic regulation of the genome.  
Epigenetic regulation can come in the form of DNA methylation and/or histone 
modifications. The modifications that occur during early embryonic development can be 
heritable to subsequent daughter cells in the lineage [25]. These modifications help to shape 
the developmental plan from the zygote stage and throughout development. Substantial, 
research has focused on environmental factors present in vitro and how they may effect the 
establishment of DNA methylation and histone modification patterns of the early embryo 
[26]. With the increase use of in vitro embryo production in both humans and livestock 
species, research into epigenetic patterns is important in order to understand chromatin 
remodeling of the early embryo. Moreover, how these perturbations to the chromatin may 
lead to subsequent manifestation of abnormal phenotypes associated with ARTs.  
 
DNA Methylation and Hydroxymethylation 
DNA methylation is an epigenetic mechanism that can be used to modulate the 
transcriptional status of mammalian cells. DNA methylation has been associated with playing 
5 
 
a vital role in transcription, chromatin structure, genomic imprinting, embryonic 
development, and chromatin stability [27-30].  Of the different types of DNA methylation, 
the fifth carbon position of cytosine (5mc) has been popularly studied and is shown to be 
inherited through somatic cell division [31, 32].  Thus far, most studies examining DNA 
methylation have focused on CpG islands [33, 34]. CpG islands are regions of the DNA 
where a cytosine nucleotide is followed by a guanine nucleotide and are typically located 
near the transcription start sites (TSS) of genes. Cytosine methylation at the CpG sites in 
promoter regions are often associated with a decrease in transcriptional activity due to 
inhibition of the binding of RNA polymerase, thus inhibiting gene transcription [35, 36]. 
However, this is not always true as it has been shown that 5mc levels have been associated 
with both a positive and negative correlation on regulating gene transcription [37].  
The DNA methyltransferases (DNMTs), are a conserved family of proteins that play 
a key role in DNA methylation and are considered to be necessary for mammalian 
development [38]. DNMT1 is considered to be maintenance protein as it is responsible for 
passing on the methylation patterns from the dividing cells onto daughter cells in order to 
maintain chromatin stability [39].  DNMT3a and DNMT3b play a pivotal role in de novo 
methylation and establishing 5mc levels in primordial germ cells and during preimplantation 
development [40].  
During the preimplantation stage, global DNA methylation patterns play a valuable 
role in epigenetic reprogramming in most mammalian species (Figure 1.1) [41, 42]. Shortly 
after fertilization, the paternal and maternal genome undergo asymmetrical demethylation 
patterns that converts 5mc to 5-hydroxymethylcytosine (5hmc) [43-46]. Hydroxymethylation 
in 5mc in the early embryo is mediated by the enzymes of ten-eleven translocation 1 (TET1), 
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TET2, and TET3 [47, 48]. In mice, suppression of TET1 in the early embryo resulted in a 
bias towards trophectoderm differentiation [49]. These findings in mice suggest that 5hmc 
plays a role in differentiation and proper gene expression profiles in the early embryo. 
However, examples in sheep and cloned embryos, from a variety of species, proved that this 
methylation pattern is not always essential for embryo viability [42, 50, 51]. 
 
 
 
 
 
Figure 1.1 – DNA methylation patterns in primordial germ cells and early embryo in mice 
[41]. 
 
 
 
5mc and 5hmc patterns established during the early stages of preimplantation 
development are thought to be a necessary for viability of the early embryo [52]. After 
fertilization the early stages in embryo development are controlled by maternal mRNA and 
proteins. Genome activation is needed in the early embryo for it to synthesize new protein 
and thus allowing further cleavage stages to take place [53]. During this reprogramming 
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event, DNA methylation has been shown to associate with chromatin modifiers to aid in this 
reprogramming process.  
Imprinted genes have been shown to bypass regular DNA methlylation patterens 
present in the  early embryo [54]. Imprinted genes were first discovered in mice and it was 
revealed that it was required for both the paternal and maternal allele to create a viable 
embryo [55]. These allele specific patterns have been shown to be improperly maintained by 
epigenetic factors that give rise to abnormal phenotypes that are associated with ARTs 
[56,57]. Ambnormal regulation of imprinting genes has been shown to be the problem with 
loss of imprinting and abnormal placentaion during fetal development [58,59]. Finding the 
epigenetic factors that cause this abnormal regulation of imprinting genes in the early embryo 
would be beneficial for future development.  
 
Histone Modifications  
In 1964, it was first discovered that acetylation and methylation of core histone 
proteins are associated with changes in RNA synthesis [60]. Two copies each of the core 
histone proteins of H2A, H2B, H3 and H4 aid in packaging DNA and together form the 
nucleosome [61]. The DNA wrapped around these histones are approxamitaly 147 base pairs 
(bp) long, while linker DNA connects the histones to one another [62]. Histone modifications 
take place on these core proteins are associated with facilitating gene transcription based on 
the accessibility of the chromatin [63]. Modifications to histone tails are key regulators for 
chromtin assembly and transcriptional activity [64]. The most commonly studied 
modifications to histone tails include methylation, phosphorylatin, acetylation, and 
ubiquitation [65].  
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Histone methyltransferases (HMTs) are key components of epigenetic 
reprogramming, as they are associated with the initiation of gene expression [66]. Many 
different mechanisms are found to play a role in this process. Some of these histone 
methylation sites include, but are not limited to, histone 3 lysine 4 (H3K4), H3K9, H3K20, 
H3K27, H3K36, and H3K79. Methylation of H3K4, H3K36 and H3K79 have been 
associated with a more acitve chromatin while H3K9 and H3K27 have been associated with 
transcriptionally repressed chromatin [67,68]. The methylation on the histone tails can be 
quite specific as it can be mono-, di-, and tri-methylated, with trimethylation generally 
having the most substantial effect on regulation of gene expression [69].  
Two major protein groups, the Trithorax group (TrxG) and Polycomb group (PcG), 
aid in maintating the methylation status on histone tails and are associated with playing a role 
in the cell cycle (Figure 1.2) [70]. The TrxG and PcG of proteins are also able to exchange 
their binding sites with histones multiple times throughout cell divisions, thus showing 
histone modifications can be erased and re-established [71]. In general, the TrxG of proteins 
are associated with leaving the chromatin more accessible for gene transcription while the 
PcG of proteins has an inverse function.  
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Figure 1.2 – Overview of the role of Mixed Lineage Luekemia 1 (MLL1) on chromatin 
remodeling. MLL1 is a component of Trithorax Group, and Polycomb Group (PcG) role 
during the cell cycle and how they exchange their binding sites with histones multiple times 
throughout cell division. The resulting effect is condensation and relaxation of the chromatin 
[70].  
 
 
 
The TrxG and PcG proteins work together to regulate Homeobox (HOX) genes 
expression during early embryonic development. Regulation of H3K4 by the TrxG and 
H3K27 by the PcG is critical for HOX gene expression and the layout of developmental plan 
for the early embryo [72]. Abnormal HOX gene expression has been linked to atypical 
development throughout the body including skeletal, reproductive, and digestive systems 
[73,74].  To date, the majority of studies investigating the role of histone methylation on the 
control of HOX gene expression and other histone modifications have been completed by 
using a mouse model [75]. 
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Biomedical Animal Models 
The majority of studies of  epigenetic modifications during the preimplantation period 
have used the mouse as the mammalian model. However, differences in terms of epigenetic 
reprogramming and epigenetic regulation of gene expression between species is apparent 
[76]. Therefore, defining key epigenetic modifiers during preimplantation development in 
bovine is valuable as they are a biologically more relevant model to the human as compared 
to the mouse [77]. Cattle are also an economically important livestock species where ARTs 
are often used, making bovine studies relevant in human medicine and agricultural industries. 
 Reproductively, the mouse has a shorter preimplantation and gestational period (21 
days) when compared to humans (280 days). Cattle are more similar to humans in gestational 
length (approximately 282 days, depending on breed) [78]. During preimplantation 
development, there are noticeable differences in embryo development when comparing 
humans to mice and cattle. Mice reach the blastocyst stage of embryonic development on 
Day 3.5 as compared to humans and bovine (Day 5-6 and Day 6-7 respectively) [79]. 
Embryonic genome activation also varies between the mammalian species as the mouse 
genome activation occurs at the two-cell, humans begin at the four-cell stage, and bovine at 
the 8-16 cell stage [80]. It has also been shown that the bovine genome is more comparable 
in alignment to human genome than mice [81, 82].  
With over 95% of studies analyzing gene function occurring in mice, utilizing animal 
models that are genetically more similar to humans would be beneficial [83]. Utilizing the 
bovine as a research model can benefit the cattle industry as well as providing a better 
understanding of epigenetic regulation, which could help increase pregnancy rates and 
decrease disease pathogenesis that are associated IVP embryos. With the increase use of IVP 
11 
 
and commercially available oocytes in cattle, this further makes the bovine an attractive 
research model.  
 
Tools for Studying Functional Genomics 
RNA Interference  
RNA interference (RNAi) is an evolutionarily conserved mechanism that has been 
associated with modulating gene expression in eukaryotes. RNAi was first discovered in 
plant species and was found to play a role in translational repression by post-transcriptional 
gene siliencing [84]. It was later shown that double stranded RNA (dsRNA) caused the 
silencing of the targeted genes  [85]. The use of RNA interference can target specific RNA 
sequences with high specificity base pairing. This is achieved in mammalian cells by long 
dsRNA that are cleaved, by the enzyme Dicer, into short double-stranded RNA that are 
approximately 21 to 26 nucleotides long [86]. This RNA induced silencing complex (RISC) 
contains two single-stranded RNAs that consist of a guide strand and a passenger strand that 
results in the passenger strand binding to a specific sequence of the mRNA [87]. Gene 
silencing by RISC is achieved by three different mechanisms: homology dependent mRNA 
degradation, translational suppression, or transcriptional gene silencing [88]. This can be 
utilized in cells and embryos by delivering double stranded siRNAs to a specific sequence to 
mediate post-transcriptional silencing and achieve reduction of protein [89]. 
 
CRISPR-Cas9 
The type II prokaryotic clustered regularly-interspaced short palindromic repeats 
(CRISPR) when combined with the DNA endonuclease enzyme Cas9 has been shown to be 
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effective for precise genome editing in mammalian cells [89]. CRISPR-Cas9 is a bacterial 
adaptive immune system that has been engineered to function in eukaryotic cells in a quick, 
efficient, and low cost manner [90]. It can be designed to target a specific location to disrupt 
gene function with a Cas9 enzyme and a 20 base pair guide RNA target sequence adjacent to 
a PAM site (3’ NGG). After the guide RNA aligns the Cas9 enzyme to a specific sequence, 
Cas9 will recognize the PAM site and perform a double strand break. The double strand 
break is then repaired by nonhomologous end joining (NHEJ); an error prone repair 
mechanism that frequently causes insertion or deletions (InDels) in the DNA.  These InDels 
will likely cause a frameshift mutation in the coding sequence, thus disrupting the function of 
the gene. It has been shown that CRISPR/Cas9 can have a wide array of functions from 
knockout and insertion of certain gene sequences to repair mutations [91, 92].  This wide 
spread high specificity is useful for analyzing the function for different genes. Since the 
result is the loss of gene function, it is also an effective tool for analyzing gene function in 
the early embryo [93]. 
 
Bovine Uterine Environment for Transfer and Collection 
In vitro embryo culture systems can only support the development of the bovine 
embryo until shortly after the blastocyst embryo is hatched out of the zona pellucida. After 
this point in time, the embryo requires an in vivo environment for continuation of 
development. In bovine, there is a period of development after the blastocyst stage where the 
embryo undergoes rapid elongation before attaching to the endometrial cells of the uterus 
[94]. The initiation of elongation of the blastocyst occurs on Day 12 to 14  in bovine. In the 
uterine environment, progesterone works to stimulate blastocyst growth and elongation 
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during this pre-implantation period [95-97]. The elongation of the trophectoblast cells is 
critical for the for the release of interferon tau (IFNT) for maternal recognition of pregnancy 
in cattle [98]. If an insufficient quantity of IFNT is produced, PGF2-alpha will be released to 
lyse the corpus lutea and thus contining the estrus cycle.  
Embryos require transfer into estrus synchronized recipients in order to replicate the 
uterine environment for the Day 7 embryos [99]. Estrous synchronization protocols are 
common in the embryo transfer industry, with the standard CIDR method being used for 
timed embryo transfer [100]. In order to avoid surgical procedures on recipient females, 
embryos can be collected on Day 17 of development [101]. On Day 17 embryo elongates into 
a long filamentous conceptus to contains a small embryonic disc [102]. On Day 19 the 
elongated bovine conceptus will begin binding to the uterine epithelium [103]. Once this 
binding begins, conventional nonsurgical embryo collection would no longer be possible for 
examination of the conceptus. Later in development, the elongated filamentous 
trophectoderm will become the placenta, while the embryonic disc will develop into the 
fetus. In previous studies, it has been shown that transferring of up to eleven embryos per 
recipient can be achieved while still maintaining elongation and embryo viability [104]. 
Collection of conceptuses at this time allows for non-invasive techniques to the recipient that 
will allow her to be used for future experiments.  
 
Epigenetic Modifiers in Bovine Embryos 
 DNMTs and HMTs have previously been studied in bovine preimplantation embryos 
by using a RNA interference approach [105-109]. All of the genes studied, when suppressed 
in the early embryo, have had an inhibitory effect on preimplantation development up to the 
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blastocyst stage (Table 1.1). Due to morphological and developmental changes caused by the 
suppression of the DNMTs and HMTs, analysis of ASH2L will give valuable information on 
its role during preimplantation development in bovine. Furthermore, no member of the TrxG 
of proteins has yet to be analyzed for their role during bovine preimplantation development. 
 
 
 
DNA 
Methyltransferases 
Histone 
Methyltransferases 
DNMT1 SUZ12 
DNTM3A SMYD3 
DNTM3B EHMT2 (G9A) 
LSH SETDB1 
 SUV3-9H1 
 SUV4-20H1 
 
Table 1.1 – DNMTs and HMTs previously studied during bovine preimplantation 
development.  
 
 
 
Ash2 (Absent, Small, and Homeotic)-Like (ASH2L)  
Ash2 was first discovered in Drosophila and was determined to belong to the TrxG 
gene family as a positive regulator of gene expression. The ASH2L protein is a known HMT 
that plays a role in H3K4 [110]. ASH2L is also a core component of the Trithorax group of 
proteins, also known as the Mixed Lineage Leukemia (MLL) protein. The Trithorax group is 
a multiprotein complex that requires the presence of ASH2L, WD Repeat Domain 5 
(WDR5), Retinoblastoma Binding Protein 5 (RBBP5), Dpy-30 Histone Methyltransferase 
Complex Regulatory Subunit (DPY30) and Host Cell Factor (HCF) proteins in order for the 
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complex to be in an active state [111]. Its interaction with RBBP5 is necessary for complex 
integrity and activity regulation [112]. The binding of ASH2L to DPY30 is important for the 
regulation of the trimethylation of H3K4 [113, 114].  
This active state could be a key factor in the epigenetic reprogramming as it is a 
member of the MLL complex that regulates the methylation of the histone H3 Lysine 4 
(H3K4) and facilitates the chromatin to be more accessible for transcription [115, 116]. It has 
been shown that trimethylation of H3K4 is associated with active gene transcription and thus 
plays a role in developmental regulation. If improperly maintained it can lead to disease 
pathogenesis, including cancer in mammals [117]. ASH2L and the trimethylation of H3K4 
are associated with increased transcription of HOX genes (Figure 1.3) [118, 119].  
 
 
 
 
Figure 1.3 – Role of ASH2L on H3K4me3 and HOX gene expression. ASH2L when 
complexed with Mixed Lineage Leukemia (MLL), WDR5, RBBP5, and DPY-30 increases 
H3K4me3 levels and HOX gene expression during development (South and Briggs, 2011).   
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From the 5’ to 3’ end of the ASH2L gene, it contains a plant homeodomain (PHD) 
finger, a wing helix domain, a SPIa/RYanodine receptor (SPRY) domain, and a DPY-30 
binding-Motif [120, 121]. The wing helix domain is associated with binding of ASH2L to the 
DNA and when this region is disrupted, it reduces the localization of ASH2L within the 
HOX locus.  The SPRY domain on the C-terminal end of the ASH2L gene works with 
RBBP5 to regulate the methyltransferase activity of the Trithorax group of proteins [122]. 
For gene studies, it would be necessary to target these regions of the gene in order to have a 
disruptive phenotype. 
Previous work in mice has shown that suppression of ASH2L globally decreases 
H3K4 trimethylation levels [115]. ASH2L-null mice have a lethal phenotype at embryonic 
Day 3.5 to 8.5 [123]. ASH2L-null embryos achieved the blastocyst stage but were non-viable 
in mid-gestation. Furthermore, ASH2L-null embryos were unable to establish embryonic 
stem cell lines. Depletion of ASH2L in mouse embryonic stem cells, led to a loss of 
pluripotency and a repressed transcriptional status [124]. Additionally, over expression of 
ASH2L is related to tumorigenesis and diseases in adults [125, 126]. Regulation of this gene 
in the early embryo is important due to the detrimental side effects caused by both over and 
under expression of ASH2L. ASH2L is also important in stabilizing X chromosome 
inactivation when paired with Saf-A [127]. The effect of the ASH2L on imprinted genes has 
yet to be analyzed. ASH2L has not been studied in mammalian models other than mice.  
 
Research Goal and Hypothesis 
Given the importance of ARTs in both human medicine and livestock industry, in 
vitro production of high quality, epigenetically normal embryos is essential. Further 
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investigation of the epigenetic modifiers during the critical period of preimplantation 
development is necessary to develop production systems capable of achieving this endpoint. 
The overall goal of this research is to characterize the role of ASH2L during early bovine 
preimplantation development. Our initial hypothesis was depletion or deletion of ASH2L 
would alter embryonic development during the preimplantation period. It was also suspected 
that suppression of ASH2L in the early embryo would cause variations in histone 
modifications and result with an altered transcriptional status. We utilized experimental 
techniques to examine embryonic development when ASH2L is depleted or deleted in the 
early bovine embryo.  
We investigated the suppression or knockout of ASH2L in the early embryo by 
microinjection of siRNAs or CRISPR-Cas9 complexes into bovine zygotes. In vitro produced 
blastocysts depleted of ASH2L were evaluated in comparison with controls for epigenetic 
modifications by immunocytochemistry (ICC). ASH2L suppressed embryos and appropriate 
controls were transferred into recipient females and collected on Day 17 to better 
characterize preimplantation development. On Day 17 of development, global transcriptome 
analysis was performed by RNA-seq to examine if alterations were present in ASH2L 
embryos targeted with RNA interference. The data collected from these experiments have 
helped to define the role of ASH2L during preimplantation development and give insight on 
possible factors that can inhibit bovine IVP systems.  
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CHAPTER II 
MATERIALS AND METHODS 
 
RNA Interference Targeting ASH2L in Bovine Cells 
Stealth siRNAs (Invitrogen) targeting the bovine ASH2L gene were tested in Madin-
Darby bovine kidney (MDBK) cells. Three siRNA sequences were designed to target the 
sense and antisense strand of the bovine ASH2L mRNA (NM_001205473.1): ASH2L siRNA 
349 (5’ –GGUAGAGCUGCAGUGUGGAAUAUGU- 3’), ASH2L siRNA 1124 (5’ –
GAUCUCUACAGAGCCUGCUUAUAUG- 3’) and ASH2L siRNA1492 (5’ –
CGAAGAUACAGAGACAGCCAAGUCA- 3’). Sequences shown correspond to the sense 
strand, with numbers indicating the target positions of the bovine ASH2L transcript. Stealth 
siRNAs were resuspended in nuclease-free water at a 20 µM concentration and aliquoted to 
avoid repeat freeze/thaw cycles. Individual or combined siRNAs were diluted to 20 nM and 
transfected into MDBK cells using Lipofectimin 2000 (Invitrogen). Control MDBK cells 
were transfected with a non-targeting siRNA (CY3, Invitrogen).  RNA was extracted from 
transfected cells with a RNeasy kit (Qiagen) by following manufacturer guidelines. RNA was 
converted to cDNA and ASH2L expression ascertained by quantitative PCR (qPCR). When 
ASH2L targeted cells were compared to the CY3 control cells, the siRNAs of 349 and 1124 
were shown to be the most effective at supressing ASH2L (Figure 2.1). An even mixture of 
the dual Stealth siRNAs were subsequently used for all experiments targeting the depletion 
of ASH2L in the embryo. 
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Figure 2.1 – ASH2L expression levels in cell lines transfected with siRNAs. The suppression 
of ASH2L is observed when compared to the control group (CY3) in Madin-Darby bovine 
kidney (MDBK) cells (Courtesy of Mike Peoples).  
 
 
 
CRISPR-Cas9  
Plasmid Design and Linearization 
 The plasmid pSpCas9 (BB)-2A-Puro (PX459) from Addgene was used for all 
CRISPR-Cas9 experiments for targeting the ASH2L gene (Figure 2.2). PX459 was 
developed by the Zheng lab (MIT) and is a modified version of the PX330 CRISPR plasmid. 
PX459 contains two expression cassettes that include the hSpCas9 (Cas9) and the small 
guide RNA (sgRNA). The chimeric backbone of the plasmid has a tracrRNA (85 
nucleotides) sequence downstream of the Bbs1 cut site that allows for increased efficiency of 
the sgRNA. PX459 also contains the selection markers of a puromycin (Puro) and ampicillin 
(Amp).  
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Figure 2.2 – Design of the PX459-Puro plasmid. PX459-Puro was used for insertion of guide 
RNA (also known as sgRNA) for future experiments targeting ASH2L gene with CRISPR-
Cas9 (Courtesy of Carlos Pinzon). 
 
 
 
 Linearization of the PX459 (1 µg) was performed with a restriction digest by the 
following conditions:  5 µl Buffer 2.1 (NEB), 1 µl Bbs1 (NEB) enzyme, and brought up to 50 
µl volume with nuclease-free water.  The reaction was mixed well and digested at 37ºC for 
one hour and then heat inactivated at 65ºC for 20 minutes. The linearized plasmid was stored 
at -20ºC. 
 
Small Guide RNA Design 
 The bovine ASH2L coding sequence was retrieved from the NCBI (NM_00120547) 
database.  Each intron-exon junctions and PAM sequences (3’-NGG) were identified within 
the ASH2L mRNA coding sequence. Small guide RNAs were identified and then examined 
for off-targeting effects with NCBI Blast. After sgRNAs were verified to target the ASH2L 
gene and had no off-targeting effects, oligonucleotides (Invitrogen) were ordered for both the 
sense and antisense strand (Table 2.1). Additional nucleotides for the Bbs1 cut sites were 
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added to the sense and antisense strand for insertion into previously linearized plasmid 
(Figure A1). Oligonucleotides (Invitrogen) were resuspended in nuclease-free water at a 100 
µM concentration and stored at -20ºC. 
 
 
 
Target Location Strand Oligonucleotide 
Sequences 
PAM 
Sequence 
ASH2L 
Guide 1 
100 Sense CACCGAGAAGAAGGGGAGACGAAGC AGG 
Antisense AAACGCTTCGTCTCCCCTTCTTCTC  
ASH2L 
Guide 2 
49 Sense AAACGGCCCCGGCAGCAGCTGCTAAC  
Antisense CACCGTTAGCAGCTGCTGCCGGGCC TGG 
ASH2L 
Guide 3 
1422 Sense CACCGAAACACTACTCTTCTGGCTA CGG 
Antisense AAACTAGCCAGAAGAGTAGTGTTTC  
ASH2L 
Guide 4 
1439 Sense CACCGCTACGGACAGGGAGACGTCC TGG 
Antisense AAACGGACGTCTCCCTGTCCGTAGC  
 
Table 2.1 – Oligonucleotide sequences designed for targeting ASH2L coding sequence with 
Bbs1 insertion nucleotides. Target sequences are underlined for each of the individual 
sgRNAs with PAM sequences located on the target allele. Numbers indicate the target 
location in the ASH2L coding sequence. 
 
 
 
Primer Design 
Primers were designed to amplify the ASH2L target sites for CRISPR-Cas9 
experiments. The ASH2L sequence was retrieved from NCBI (NM_00120547) and 
NetPrimer (Premier Biosoft) were used to design primers for amplification of target 
sequences of the sgRNAs (350-600 bp). The forward and reverse primer were located at a 
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minimum of 100 bp away sgRNA target sequences (Table 2.2). The following conditions 
were used for selection of PCR primers: 20-22 nucleotides in length, Tm of 57-60˚C, GC 
content of 40-60%, and minimal dimerization. Oligonucleotides were reconstituted from 
lyophilized pellets with nuclease-free water at a concentration of 100 µM. 
 
 
 
Target Strand Primers Annealing 
Temperature 
Amplicon 
Length 
ASH2L 
Target 1 
Forward CTTTACTGTTTGAAGGTGAGCAG 60ºC 386 
Reverse TAGGTTCGGAGGAGGGATG 
ASH2L 
Target 2 
Forward TGGATTTTGTGGGCATAATG 57ºC 573 
Reverse CTAGGTATTGGGCATTTGGAC 
 
Table 2.2 – Primers sequences for DNA amplification of ASH2L target sites.  
 
 
 
Insertion of sgRNA into CRISPR Plasmid 
Oligonucleotides were phosphorylated individually with the following components: 2 
µl of oligonucleotide stock (100 µM, Invitrogen), 2 µl of 10X T4 DNA ligase buffer (NEB), 
2 µl of T4 PNK (NEB), and brought to a 20 µl volume with nuclease-free water. The reaction 
was mixed well and then incubated at 37˚C for 1 hour. T4 PNK was then heat inactivated at 
65˚C for 20 minutes. Phosphorylated oligonucleotides were combined, 5 µl of sense and 
antisense, with 90 µl of nuclease-free water. The mixture was incubated for 3 minutes at 
95˚C and then the reaction was slowly cooled to room temperature for one hour. To ligate the 
plasmid, 1 µl of annealed oligonucleotides was combined with 1.5 µl of linearized PX459, 5 
µl of Rapid DNA Ligation Buffer (Rosche), 1 µl of Rapid DNA Ligation (Rosche), and 
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brought to a 10 µl volume with nuclease-free water. The reaction was mixed well and 
incubated at room temperature for 10 minutes. 
After the reaction, 5 µl of the ligated mixture was added to 25 µl of TOP10 
competant cells (Invitrogen) and was placed on ice for twenty minutes. The mixture was then 
heat shocked for 60 seconds at 42˚C to start transformation of the bacteria. After heat shock, 
the mixture was left on ice for two minutes to finalize the transformation. To maximize 
transformation efficiency, 200 µl of room temperature S.O.C Medium (Invitrogen) was then 
added to transformed bacteria and subsequently shaken for 1 hour at 37˚C. From the mixture, 
150 µl was pipetted onto a prewarmed LB agar-ampicillin plate and placed in a 37˚C 
incubator for 12-16 hours. Plates were then examined for colony formation and moved to 4˚C 
for storage.  
 Individual colonies were selected and placed into tubes with 2 ml of LB Broth 
(Invitrogen) supplemented with 1 µg/ml of Ampicillin. Tubes were shaken overnight at 37˚C 
to propagate the bacteria. After propagation, bacterial DNA was then isolated from the LB 
Broth with Qiagen Miniprep Kit (Qiagen). DNA was examined for concentration, purity 
(NanoDrop, Thermo Scientific), and then stored at -20˚C. 
  
Verification of sgRNA Insertion into Plasmid 
 Purified DNA (1 µg) from the transformed plasmids underwent a restriction digest to 
determine if the guide sequence was inserted into PX459. DNA was double digested with 0.5 
µl Ecor1 (NEB), 0.5 µl Bbs1 (NEB), 2 µl Buffer 2.1 (NEB), and adjusted the volume to 20 µl 
with nuclease-free water. A positive control of untransformed PX459 and negative control 
with water were substituted for the transformed plasmid. The mixture was digested for 1 hour 
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at 37˚C in a humidified incubator and then heat inactivated at 65˚C for 20 minutes. The 
reaction was then analyzed on a 1% agarose gel to see if the Bbs1 site was destroyed from 
the insertion of the sgRNA (Figure A2).   
 
Transfection of CRISPR-Cas9 Complex into Bovine Cells 
Culture of Bovine Fibroblast Cells 
Early passage bovine fibroblast cells, produced at the Reproductive Science Lab 
(Bryan, TX), were maintained in T75 tissue culture flasks (VWR) and cultured in an 
incubator at 37˚C, 5% CO2, and humidified air. Cells were cultured in Dulbecco’s Modified 
Eagle Medium with nutrient mixture F-12 (DMEM/F12, Life Technologies) supplemented 
with 10% fetal bovine serum (FBS, Atlanta Biologicals), 1% antibiotic/antimycotic (Anti-
Anti, Life Technologies), and 50mg/ml gentamicin (Life Technologies). Cells were passed 
once they obtained a confluency of 80-90% in order to maintain cell viability. During the 
passage of fibroblast cells, the cells were washed twice with 10 ml of calcium and 
magnesium free DPBS (Life Technologies) and then 2 ml of trypsin (Trypsin-EDTA 0.25%, 
Life Technologies) was added onto to the cells. The cells incubated in the trypsin at 37˚C 
until the cells released from the bottom of the flask. Once the cells were released, the trypsin 
was neutralized with 10% culture media (DMEM/F12, 10% FBS, 1% antibiotic-antimycotic 
(Gibco), and 50 mg/ml gentamicin), and centrifuged for 5 minutes at 200x g. The 
supernatant, with the trypsin, was removed and replaced with prewarmed culture media and 
divided evenly amongst new culture flasks. For transfections, fibroblast cells were plated 
eighteen hours pretransfection into a 6-well polystyrene culture dish (VWR) so monolayer of 
cells reached 70-80% confluency at the time of the transfection.  
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Preparation of PolyJet-DNA Complex for Transfection 
 Plasmid DNA (1 µg), with inserted sgRNA, was diluted in 50 µl of DMEM with high 
glucose (Gibco) in a 0.6 ml conical tube. In a separate 0.6 ml conical tube, 3 µl of PolyJet 
(SignaGen Laboratories) was diluted in 50 µl of DMEM with high glucose. Once mixed, the 
diluted PolyJet was added to plasmid DNA and incubated for 12 minutes at room 
temperature to allow the PolyJet/DNA complex to form. After incubation, the PolyJet/DNA 
complex was evenly added drop by drop to bovine fibroblast cells and incubated at 37˚C for 
12 hours. Fresh 10% culture media (2 ml) was then added to each group of cells. For each 
transfection, the plasmid PX458-GFP (Addgene, Plasmid #48138) was added to a separate 
group of cells to serve as a positive control and allowed visual determination of transfection 
efficiency (Figure A4).    
 
Puromycin Selection and Single Cell Colony Propagation 
After transfections, bovine fibroblast cells were allowed to recover for 36 hours in 
10% culture media before selection of positive colonies with puromycin (Invitrogen). 
Puromycin, at a concentration of 1 µg/ml, was added to 10% culture media for 72 hours or 
until single cell colonies were visible. Singe cell colonies then recuperated in 20% culture 
media (DMEM/F12, 20% FBS, 1%Anti-Anti, and 50mg/ml Gentamicin) for 24 hours. Clonal 
rings (Scienceware) was then used for selection of single cell colonies. Trypsin was added 
drop by drop until it covered the cell and was incubated at 37˚C for 5 minutes or until the cell 
released from the well. The 20% culture media was added to clonal ring to collect cell and 
was transferred to a 24-well polystyrene plate (VWR) to continue culture.  
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DNA Extraction and Preparation for Sequencing 
DNA Extraction from Bovine Cells 
A DNeasy kit (Qiagen) was used to isolate DNA from the proliferated single cell 
colonies. DNA extraction was performed according to manufacturer guidelines except 30 µl 
of elution buffer was used to increase DNA concentration. DNA was examined for 
concentration, purity (NanoDrop, Thermo Scientific), and stored at -20˚C or amplified 
immediately by PCR. 
 
DNA Extraction from Embryos 
On Day 8 post IVF, blastocysts from sgASH2L Target 1 and Target 2 groups were 
washed twice through DPBS to rinse any culture media and mineral oil away. Embryos were 
then exposed to Tyrode's Salt Acidic (TSA, Invitrogen) for 2 to 5 minutes or until the zona 
pellucida was removed. The embryo was then washed three more times in DPBS and placed 
into 10 µl of lysis buffer (Buffer AL, Qiagen) with a sterile Drummond pipet. A new pipet 
was used for each embryo to avoid cross contamination of the DNA. Embryos were then 
stored at -20ºC until DNA extraction.  
Embryos were thawed and 50 µl of lysis buffer was added to each sample. Lysed 
embryos were exposed to EDTA, Tris·HCl, and Proteinase K (Qiagen); and incubated at 
45ºC for 1 hour to digest any proteins. After incubation, a 1:1 ratio of phenol chloroform: 
isoamyl alcohol (Sigma) was added to each embryo sample. Embryos were vortexed and 
centrifuged at 13,000x g for 10 minutes at room temperature. The aqueous layer (top layer) 
was transferred to a sterile 0.6 mL conical tube (VWR). Double the volume of 100% ethanol 
was added to precipitate the DNA and was stored overnight at -20ºC. Precipitated DNA was 
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pelleted by centrifugation at 13,000x g for 30 minutes at 4ºC. Ethanol was then removed 
from the pelleted DNA and washed again with freshly prepared 70% ethanol at 13,000x g for 
10 minutes at 4ºC. Ethanol was removed from the pellet and was air dried for 5 to 10 
minutes. The dried pellet was resuspended in 10 µl of filtered TE Buffer and stored at -20ºC. 
 
DNA Amplification for sgRNA Target Regions 
DNA extracted from individual cell colonies and embryos were used for PCR 
amplification of target regions for the sgRNAs. A mastermix was made with the following 
components for each reaction: 2.5 µl 10X buffer (Invitrogen), 0.5 µl dNTPs (Promega), 0.5 
µl forward primer (Target 1 or Target 2), 0.5 µl reverse primer (Target1 or Target 2), 0.75 µl 
MgCl2 (Invitrogen), 0.125 µl taq polymerase (Invitrogen), and brought to a 21 µl volume 
with nuclease-free water (Table A1). The master mix was vortexed, centrifuged down, and 
aliquoted into individual PCR tubes. DNA from the individual embryo or cell colony (4 µl) 
was added to the mastermix, vortexed, and then centrifuged down. For each reaction, a 
positive bovine genomic DNA and negative water control were used. The reactions were 
placed into the thermo cycler (Peltier) and exposed to the respective conditions for sgASH2L 
Target 1 or Target 2 (Table A2 and Table A3, respectively). Once the reaction was complete, 
the samples were stored at -20ºC or went directly for gel analysis.  
 DNA from the PCR reaction was mixed with a 1:6 dilution of loading dye 
(Invitrogen) and was visually analyzed by 1% agarose (Invitrogen) gel, with GelRed 
(Phenix) being used as a nucleic acid stain. The 1kb+ ladder (Invitrogen) was used to 
reference of the size (Target 1- 386 bp or Target 2- 573 bp) of the amplified DNA. After 
positive lanes were identified, an additional PCR reaction was made as previoiusly described 
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for DNA from the individual embryos (Table A1). Positive DNA bands were stabbed from 
the gel with a 20 µl pipet tip and placed into the PCR premix. The DNA underwent an 
additional amplification in order to increase the total amount of DNA obtained from 
individual embryos. After the DNA was amplified, it was gel analyzed under the same 
conditions previously described. Once a positive lane was identified, the remaining 15 µl of 
amplified DNA was extracted with a PCR Purification Kit (Invitrogen). DNA purification 
was completed by following manufacturer guidelines with a change in the elution step. DNA 
was eluted with 25 µl of prewarmed nuclease-free water in order to increase DNA 
concentration from the colomn. DNA was then stored at -20ºC or was used for sequence 
analysis. 
 
Sequence Analysis  
DNA was examined for concentration and quality before being sent for sequence 
analysis. DNA was sequenced with an ABI PRISM(R) 3100 Genetic Analyzer at the Gene 
Technology Laboratory (GTL) on the Texas A&M campus. Plasmid DNA was sent for 
sequencing at a concentration of 400-600 ng/µl while DNA from PCR purification was sent 
at a concentration of 10ng/100bp. All sequence primers were sent in at a concentration of 6-
10 pM per sequence reaction. The Primer LKO 1.5’- GACTATCATATGCTTACCGT was 
used to sequence the PX459 plasmid for insertion of the sgRNAs (Figure A5). DNA from 
single-cell colonies and individual embryos were sequenced with the forward primer for each 
of the respective target regions. Sequences were retrieved from the GTL website and 
sequence analysis was completed with NCBI Blast to analyze sequence result with the wild 
type sequence. Chromatographs from the sequences were analyzed with ApE software to 
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examine if mutations present were suggested to be monoallelic (Figure A6) or biallelic 
(Figure A7).  
 
Bovine Embryo Production  
In Vitro Embryo Production and Culture 
Bovine oocytes were collected from a commercial vendor (DeSoto Biosciences, 
Seymour, TN) and shipped in an MOFA metal bead incubator (MOFA Global) overnight at 
38.5˚C in sealed vials containing 5% CO2 in air-equilibrated Medium 199 with Earle’s salts 
(Gibco), 10% fetal bovine serum (Hyclone), 1% penicillin–streptomycin (Invitrogen), 0.2-
mM sodium pyruvate, 2-mM L-glutamine (Sigma), and 5.0 mg/mL of Folltropin 
(Vetoquinol). Only high quality oocytes were selected for embryo experiments. Once oocytes 
were matured (22-24 hours), they were washed twice in warm Tyrode lactate (TL) HEPES 
(MOFA) media supplemented with 50 mg/ml of gentamicin (Invitrogen) while being handled 
on a 38.5˚C stage warmer. Fertilization stock medium contained the following ingredients: 
114 mM NaCl (Sigma), 3.2 mM KCl (Sigma), 25.0 mM NaHCO3 (Sigma), 0.34 mM 
NaH2PO4•H2O (Sigma), 10 mM Na Lactate (Sigma), 1µl/ml Phenol Red (Sigma), 2.0 mM 
CaCl2•2H20 (Sigma), and 0.5 mM MgCl2•6H20 (Sigma). Fertilization stock medium was 
supplemented the day of IVF with 250-mM sodium pyruvate (Sigma), 1% penicillin–
streptomycin (Gibco), 6 mg/mL of fatty acid–free BSA (Sigma), 20-mM penicillamine 
(Sigma), 10-mM hypotaurine (Sigma), and 10 mg/mL of heparin (Sigma). The fertilization 
medium was pre-equilibrated at 38.5˚C in a 5% CO2 humidified air incubator for at least 2 
hours before the start of IVF procedures. Oocytes were washed once in bovine fertilization 
media and then was placed into the fertization well. Frozen semen (Logan 62M27, 
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Beefmaster, Lot 03237) was thawed at 35˚C for 1 minute, then live/dead separated by 
centrifugation at 200x g for 20 minutes in a density gradient medium (Isolate, Irvine 
Scientific). The supernatant was removed and 200 µl of sperm pellet was resuspended in 2 
ml of pre-equilibated bovine fertilization media and centrifuged at 200x g for 10 minutes. 
The sperm pellet was removed and placed into a warm 0.65-ml microtube (VWR). A 1:20 
dilution of the semen pellet in ddH20 was placed onto a hemocytometer with averages the 
two counts being used to calculate sperm concentration. Semen was diluted in pre-
equilibrated fertilization media before bulk fertilization in Nunclon four-well dishes (VWR) 
containing up to 50 matured oocytes per well at a concentration of 1.0  x 106 sperm/ml. 
Embryo development for the transfers were preformed with the some modifications. The sire 
was a bos indicus bull (Suville Poncrata 102, Brahman, Lot 89387) and the following 
modifications were made to bovine fertilization media to optimize fertilization conditions for 
the sire: 20 µg/ml heparin, 2.0  x 106 sperm/ml, and fertilization occurred in 50 µl drops.  
Fertilization lasted for 16 to 18 hours in a 5% CO2 and humidified air incubator. 
Presumptive zygotes were washed out of fertilization media and placed into TL Hepes. The 
cumulus cells were removed by a 2-minute vortex in 45 µl of TL HEPES in a 0.65 ml 
microtube (VWR). Cumulus cells not removed by vortex were cleaned with a 125 µM 
stripper tip (Origio). Presumptive zygotes underwent multiple washes to be separated from 
cumulous cells. Once presumptive zygotes were cleaned, they were placed into Bovine 
Evolve medium (Zenith Biotech) supplemented with 4 mg/ml of BSA (Probumin, Millipore). 
Embryos were cultured in groups of approximately one embryo per 10 µl of culture media 
(50 embryos/500µl Bovine Evolve) in a 5% CO2 and 5% O2 humidified incubator.  Cleavage 
rates were recorded on Day 2, and viable embryos were separated from nonviable embryos at 
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this time. Embryos were monitored daily for morphologic progression, and blastocyst rates 
were recorded on Day 8 post IVF.  
  
Cas9  mRNA and sgRNA Preparation for Microinjections 
In Vitro Transcription of Cas9 mRNA   
The linearized PX459 plasmid was used for production of the Cas9 messenger RNA 
(mRNA). Production of the Cas9 mRNA was prepared by in vitro transcription (IVT) with 
the T7 mMESSAGE mMACHINE Kit (Ambion), with 1 µg of DNA template being used. 
IVT, extraction, and purification of the Cas9 mRNA was prepared by following manufacturer 
guidelines. Cas9 mRNA was resuspended in TE Buffer and analyzed for concentration and 
purity. Cas9 mRNA was then aliquoted into 0.65 ml microtubes to avoid repeated 
freeze/thaw cycles and stored at -80˚C. 
 
Production of sgRNAs for Microinjections 
 Plasmids verified for the insertion of the target sequence for ASH2L were used for 
the production of sgRNAs.  PX459 does not have a T7 promoter located upstream of the 
sgRNA sequence so a forward primer was designed with a T7 promoter on the 5’ end of the 
Bbs1 insertion region and reverse primer on the 3’ end of the tracrRNA sequence (Figure 
A8). This allows for insertion of the promoter sequence and amplification of the sgRNA 
sequence needed for in vitro transcription (IVT).  
The PCR reaction was mixed under the following conditions: 12.5 µl of Hifi PCR 
Premix (CloneAmp), 0.5 µl forward primer, 0.5 µl reverse primer, 100 ng of DNA template, 
and brought to a 25 µl volume with nuclease-free water. The T7 promoter and target 
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sequence was then PCR amplified in a thermo cycler under the appropriate conditions (Table 
A4). The DNA from the PCR was then placed on a 1% agarose gel to analyze amplification 
of the target sequence with the T7 promoter. After visual confirmation, a QIAquick Gel 
Extraction Kit (Qiagen) was used for extracting the T7 promoter and target sequence. After 
the DNA was eluted, it was analyzed for concentration and quality and then stored at -20˚C 
until future use. 
After insertion of the T7 promoter upstream of the sgRNA sequence and extraction of 
plasmid DNA, each of the plasmids were in vitro transcribed with the T7 MEGASCRIPT Kit 
(Ambion) in order to produce the sgRNAs. IVT was completed by following manufacturer 
guidelines with a 4 hour incubation time for the reaction. After terminating the reaction, the 
sgRNA was collected with a phenol:chloroform extraction and isopropanol precipitation. The 
sgRNA was resuspended in TE Buffer and analyzed for concentration and purity. The 
sgRNAs were aliquoted into 0.65 ml microtubes and stored at -80˚C. 
 
Bovine Intracytoplasmic Microinjections 
Microinjections of siRNAs Targeting ASH2L 
Presumptive zygotes were randomly assigned to three different treatment groups: 
non-injected controls (Control), non-targeting siRNA injected controls (siNULL), and 
injection with dual siRNAs targeting ASH2L (siASH2L). The siNULL embryos were 
injected with a fluorescently (Cy3) labeled negative control siRNA (Invitrogen) mixed with a 
green fluorescent dextran (Invitrogen) in  TE buffer. The siASH2L embryos were injected 
with target verified siRNAs (20 nM),  and mixed with a green fluorescent dextran in TE 
buffer. The green fluorescent dextran was used for visual confirmation of the 
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intracytoplasmic microinjections (Figure 2.3). Presumptive zygotes from the siNULL and 
siASH2L groups were injected with approximately 100 pl of there respective construct. After 
injection, fluorescent embryos were placed back into Bovine Evolve medium (Zenith 
Biotech) and cultured in a humidified incubator with the gas concentrations of 5% CO2, 5% 
O2, and 90% N2.  
 
 
 
        
Figure 2.3 – Representative image of intracytoplasmic microinjection in bovine embryos. 
Microcinjections of siRNAs targeting ASH2L or CRISPR-Cas9 complex targeting ASH2L 
into presumptive bovine zygote (A) with confirmation of microinjection taking place (B) 
(Courtesy of Jane Pryor). 
 
 
 
Microinjections of CRISPR-Cas9 Complex Targeting ASH2L  
Presumptive zygotes were randomly assigned to four different treatment groups: non-
injected controls (Control), sham-injected controls (sgNULL), sgASH2L Target 1 (Guide 1 
and Guide 2), and sgASH2L Target 2 (Guide 3 and Guide 4).  Prior to microinjections, Cas9 
mRNA and the dual sgRNAs were mixed and incubated on ice for 20 minutes to create the 
CRISPR-Cas9 target cascade. The non-targeting injection controls were made with the dual 
sgRNAs (25 ng/µl each), a green fluorescent dextran, and mixed in TE Buffer. Each 
sgASH2L target group was mixed with Cas9 mRNA (40 ng/µl), the respective dual sgRNAs 
A B 
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(25 ng/µl), green fluorescent dextran, and suspended in TE Buffer. Presumptive zygotes were 
injected with approximately 100 pl with their respective construct (Figure 2.3). After 
injection, fluorescent embryos were placed into Bovine Evolve medium (Zenith Biotech) and 
cultured in a humidified incubator with the gas concentrations of 5% CO2, 5% O2, and 90% 
N2. 
 
Expression Levels of ASH2L in Suppressed Embryos 
RNA Extraction and Reverse Transcription 
 RNA was extracted from 3 biological repititions of each treatment group at the 8-cell 
(N=15) and blastocyst (N=10) stage of development by using RNeasy Mini Kit (Qiagen). 
RNA was extracted by following manufacturer protocol with one modification. Due to the 
lower concentration of RNA present in these samples, each was eluted with 20 µl of 
nuclease-free water. RNA was DNase treated by adding 1 µl of DNase Buffer (Invitrogen), 1 
µl DNase (Invitrogen), and incubated at 65ºC for 10 minutes. Reverse transcription reactions 
were performed by using the SuperScriptII kit (Invitrogen) by combining 1 µl of 10mM 
dNTP (Promega), 1 µl of random hexamer oligonucleotides (Invitrogen), 8.5 µl of nuclease-
free water, and 2.5 µl of DNase treated RNA. The constant volume was done due to the low 
concentration of RNA from the embryos that is unable to be detected (NanoDrop, Thermo 
Scientific). The DNase treated RNA was separated into four groups for reverse transcription 
with one sample of being used to create a negative control for the qPCR step and did not 
undergo reverse transcription.  The reaction ran for 5 minutes at 70ºC and then cooled to 
room temperature. Volumes of 5 µl of SuperScriptII (Invitrogen) reaction buffer, 3 µl 
dithiothreitol (Invitrogen), and 1 µl SuperScriptII (Invitrogen) were then added to the 
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reaction mixture. The mixture was then incubated for 50 minutes at 42ºC, 20 minutes at 
45ºC, 15 minutes at 50ºC, and then 5 minutes at 70ºC. After the incubation, the cDNA 
samples were stored at -20ºC or went directly to quantitative PCR.  
 
Quantitative PCR 
 Quantitative PCR (qPCR) analysis of the cDNA was performed by using 6.25 µl of 
DyNAmo Flash SYBR Green qPCR Mastermix (Fisher Scientific), 0.25 µl Forward and 
Reverse Primer (125pM), 0.25 ROX inhibitor (Invitrogen), 5 µl cDNA (0.6 µM) or negative 
control and brought up to a volume of 12.5 µl with nuclease-free water. The reactions were 
loaded into a 96 well plate with the reactions being performed with a StepOnePlus Real-Time 
PCR system (Applied Biosystems). Relative gene expression levels from each sample was 
calculated in triplicate by using the SYBR Green comparative ΔCt method. 
 
Immunocytochemistry 
Fixing of Bovine Blastocyst Embryos 
For each treatment group (N=12), a minimum of 3 biological repitions of blastocyst 
stage embryos was removed from culture media, washed twice with DPBS (Life 
Technologies), and fixed with ice-cold 99% methanol for a minimum of one minute. 
Embryos were washed in DPBS with 0.1% Tween-20 (Sigma, 0.1% DPBS-Tween) and 
stored at 4˚C until future use.  
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Labelling for 5mc, 5hmc, and Posttranslational Histone Modifications 
Fixed blastocyst embryos were permeabilized for 15 minutes at room temperature 
with 1% Triton X-100, diluted in DPBS, and then washed 3 times for 5 minutes each in 0.1% 
DPBS-Tween. Embryos used for examination of cytosine methylation and 
hydroxymethylation were treated with 2M HCl diluted in ddH2O, for removal of the zona 
pellucida. The embryos were removed from the 2M HCl once the zona pellucida was 
dissolved (10-15 minutes). The embryos were washed through 100 mM Trizma 
hydrochloride buffer (pH 8.5) for 10 minutes at room temperature to neutralize the HCl. All 
embryo groups were washed through 0.1% DPBS-Tween and then incubated in blocking 
buffer (10 mg/mL of BSA, 2% goat serum, and 11.25 mg/mL of glycine in DPBS) overnight 
at 4˚C. Embryos were then placed into 500 µl of diluted (1:200) primary antibodies (Table 
2.4) in blocking buffer for 1 hour at room temperature. Negative control embryos were 
incubated in blocking buffer with no primary antibody present. Embryos were washed 
through blocking buffer 3 times for 30 minutes each. Alexa 488 (Invitrogen) and Alexa 594 
(Invitrogen) were diluted (1:200) in 0.1% DPBS-Tween and embryos were incubated for 1 
hour at room temperature with no light. The remaining steps were carried out with no light. 
The secondary antibody labeled embryos were washed 3 times for 30 minutes each in 0.1% 
DPBS-Tw. Hoechst (Sigma) was diluted at a concentration of 5 µg/ml in DPBS and embryos 
were added for 15 minutes at room temperature. Embryos were washed three times with 
0.1% DPBS-Tw for 5 minutes each at room temperature. Embryos were placed in a 20 
µl mounting media 50-50 solution of antifade and glycerol with a diluted 5 µg/ml of Hoechst. 
Cover slips were mounted with parafilm wax on the edge to prevent damage of the embryos 
and sealed with clear fingernail polish for storage at -20ºC.  
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Type Target Antibody  Source (cat#) 
Primary 5mc 5-Methylcytidine mAb Epigentek (33D3) 
Primary 5hmc 5-Hydroxymethylcytosine pAb Active Motif (39791) 
Primary H3K4me3 Histone 3 trimethyl Lys4 Rabbit pAb Active Motif (39159) 
Primary H3K4me2 Histone 3 dimethyl Lys4 Rabbit pAb Abcam (ab11946) 
Primary H3K9me2-3 Histone 3 di-trimethyl Lys9 Rabbit mAb Abcam (ab71604) 
Primary H3K27me3 Histone 3 trimethyl Lys27 Rabbit mAb Abcam (ab6002) 
Secondary Rabbit IgG Alexa Flour 488 Goat Anti-Rabbit IgG Invitrogen (A-11008) 
Secondary Goat IgG Alexa Flour 488 Donkey Anti-Goat IgG Invitrogen (A-11055) 
Secondary Mouse IgG Alexa Flour 594 Goat Anti-Rabbit IgG Invitrogen (A-11005) 
 
Table 2.3 – Primary and secondary antibodies used for ICC. 
 
 
 
Digital Microscopy and Analysis 
Digital imaging microscopy was performed at the Texas A&M University, College of 
Veterinary Medicine and Biomedical Sciences Image Analysis Laboratory at the Zeiss 
Stallion digital imaging workstation. Z-series were taken from individual embryos that were 
equally represented with five images taken from top to bottom of the embryo with various 
sizes and shapes depending on the embryo. Each photograph had an image of the DNA stain 
(Hoechst), image for the antibody of interest, and a merge of all images. Intensity 
measurements were taken using NIS Elements 3.0 (Nikon) software. Mean intensity 
measurements were set at a baseline level with negative control embryos that were only 
secondary antibody labeled. The mean flourescent intensity measurement for the targeting 
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antibody was divided by the DNA stained nuclei to give a fluorescent intensity ratio for each 
embryo.  
 
Embryo Transfer and Collection of Day 17 Conceptuses 
Estrous Synchronization of Recipient Cows 
 Fourteen reproductively mature cows were prepalpated and examined for 
reproductive soundness before being utilized for estrous synchronization. On the morning of 
Day -9 IVF, cycling cows were given a 2cc Combo Injection (Progesterone and Estradiol 17-
beta, Med Shop 280881) and a sterilized EAZI-BREED CIDR (Pfizer S1104231) being 
properly placed into the cycling cow. On Day -2 IVF, the EAZI-BREED CIDR was pulled 
and each cow was given a 5cc injection of prostaglandin (Lutalyse, Zoetis). The following 
afternoon, recipient cows were given a 1cc injection of Estradiol 17-beta (Med Shop 280883) 
with expected synchrony to occur the following day. The synchronized recipients waited 
until Day 7 for siNULL and siASH2L embryos to be transferred. 
 
Embryo Transfer of Day 7 Embryos 
 On Day 7 post-IVF, embryos were graded for development and quality. Blastocyst 
and morula staged embryos from the siNULL and siASH2L groups were washed into Vigro 
holding media (BioNiche) and loaded into ¼ cc straws (PETS), with two to five embryos per 
straw. Once the embryos were loaded, straws were placed in a 38.5ºC Micro-Q straw warmer 
to wait for transfer. Straws with embryos were loaded into 0.25 transfer sheaths (PETS) and 
transferred ipsilateral to the side of the corpus luteum (CL) with an embryo transfer gun (Dr. 
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Looney, Ovagenix, Bryan, TX). If no CL was present  the receipt was not used for the 
experiment.  
 
Day 17 Conceptus Collection and Morphological Analysis 
 On Day 17 post IVF, previously transferred siNULL and siASH2L embryos were 
collected from the cows (Dr. Looney, Ovagenix). Embryos were collected with one liter of 
lactated ringers supplemented with FBS, a 22 gauge BARD Foley Catheter (PETS), and 
collected into an EZ Way Filter (PETS). The filter was rinsed three times with 30 ml of 
rinsing media (BioNiche). Filters were then searched for Day 17 conceptuses within the dish 
and placed into 35 mm petri dish, with TL HEPES once found. Conceptuses were collected 
and washed five times in TL HEPES to wash the conceptus out of uterine fluid and rinsing 
media from the collection. Day 17 conceptuses were examined for an embryonic disc and 
size of the filamentous conceptus was recorded. The Day 17 conceptuses for the siNULL and 
siASH2L groups were washed out of TL HEPES five times in DPBS. Once the embryos 
were washed, they were placed in a minimal amount of DPBS and stored at -80ºC until RNA 
extraction. 
 
RNA Sequencing and Pathway Validation 
RNA Extraction and Sequencing 
RNA extraction and genomic DNA elimination from the Day 17 conceptus was 
completed by using RNeasy Plus Mini kit (Qiagen). After extraction, RNA was examined for 
concentration, purity, and then stored at -80˚C. If RNA met quality standards (1.9-2.1) and 
had high enough concentration (15 ng/µl) it was sent to the Whitehead Institute 
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(Massachusetts Institute for Technology) for RNA prep and RNA-seq. RNA from 
conceptuses from siASH2L (N=4) and siNULL (N=3) embryos were sent in for RNA-seq.  
Once quality was verified, RNA samples underwent library preparation and 
sequencing (1µg RNA in 20µl nuclease free water). Libraries were pooled for each embryo 
group and then sequenced on an Illumina HISEQ 2500 (pair-end, 2x100 bp). The RNA-seq 
reads were assessed for quality with FastQC. Adapters were removed with Cutadapt and 
processed for quality with FastX-toolkit.   
 
Pathway Validation 
 After RNA-seq analysis, significantly altered genes from common pathways had 
primers designed for quantitative PCR (qPCR).  Primers were designed as previously 
described in the methods section of Primer Design for quantification analysis of the genes in 
developmental pathways (Table 2.4). Conceptuses of the siNULL (N=4) and siASH2L (N=4) 
groups for used for analysis with duplicate reverse transcription reactions being performed. 
Reverse transcription was carried out with 250 ng/µl for each reaction by following the 
conditions as previously defined. The qPCR reaction was carried out as before described for 
analysis of ASH2L in 8-cell and blastocyst embryos. 
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Gene Strand Primer Sequence 
ZFP3 
Forward GTAGCTGCCTGAGATTGTGAG 
Reverse TGCTCCAAACTCATGACCCT 
ZNF521 
Forward ACATGATTGATGAAGGGCTG 
Reverse TTGGGTCATCGTATGGTTCTG 
DLX5 
Forward CTACCGATTCCGACTACTACAG 
Reverse ACTTCTTTCTCTGGCTGGCT 
CCL27 
Forward GTGTGAGTCCCTGTCCCAAG 
Reverse GTGCACACGAGGGAAGATCA 
WNT11 
Forward GACACTCTGACAGTGGACAGG 
Reverse GGAGCATCGGAAAACTTGGC 
GAPDH 
Forward CTGCCCGTTCGACAGATAG 
Reverse CTCCGACCTTCACCATCTTG 
SDHA 
Forward ACCTGATGCTTTGTGCTCTG 
Reverse TCGTACTCGTCAACCCTCTC 
YWAHZ 
Forward CTGAACTCCCCTGAGAAAGC 
Reverse CCTTCTCCTGCTTCAGCTTC 
 
Table 2.4 – Primers used for quantitative amplification of bovine genes. Forward and reverse 
primers were designed for both the reference genes (GAPDH, SDHA, and YWAHZ) and 
genes of interest (ZFP3, ZNF521, DLX5, CCL27, and WNT11).  
 
 
 
Statistical Analysis 
Embryo Development 
Statistical analysis for developmental data was performed using GraphPad Prism 6 
(GraphPad Software, Inc). Cleavage and blastocyst rates underwent an arcsine square root 
transformation to make the distribution normal. A One-Way ANOVA was used to compare 
the means of the three treatment groups, alpha was set at 0.05. If significant differences were 
observed a Tukey HSD test was used to determine which development group was significant.  
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Real-time Quantitative PCR 
CT values from three biological replicates  were normalized to the geometric mean of 
the bovine reference genes (GAPDH, SDHA, and YWHAZ) [128].  Relative gene expression 
levels were obtained in triplicates by using the ΔΔCT method. Values obtained were then 
analyzed by the GraphPad Prism 6 (GraphPad Software, Inc). Data underwent log 
transformation to make data more symmetrical. A One-Way ANOVA was used to compare 
the means of the three treatment groups, alpha was set at 0.05. If significant difference was 
observed a Tukey HSD test was utilized to determine what treatment groups was significant. 
Analysis with only two treatment groups was performed with a Student t-test.    
 
Immunocytochemistry 
Statistical analysis for fluorescence intensity ratios generated by ICC was completed 
with the software program JMP (SAS software). Developmental data was checked for 
normality with a Shapiro-Wilk test with outliers within each treatment group being identified 
with Quantile Range Outliers. A One-Way ANOVA was used to compare the means of the 
three treatment groups, alpha was set at 0.05. If significant differences were observed, a 
Tukey HSD test was performed.  
 
RNA Sequence 
Day 17 conceptuses of similar morphological sizes were compared with each other 
for RNA-seq analysis. RNA expression levels were determined with Cuffmerge and 
Cuffdiff.  Statistical analysis and visualization was performed with R, using RStudio running 
cummeRbund. Read depth was a minimum of ten counts per mRNA for each gene. A log 
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ratio of 1.5 was used to determine the threshold. Pathway analysis was examined by using 
Ingenuity software with a significant value set at p<0.05. 
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CHAPTER III 
RESULTS 
 
Embryo Development 
RNA Interference Targeting ASH2L 
After five rounds of IVF, embryos (N=1,309) were examined for cleavage and 
blastocysts rates between the Control, siNULL, and siASH2L groups. Analysis of embryo 
cleavage rates showed no significant difference between each of the treatment groups 
(p=0.27, Figure 3.1, Table 3.1). On Day 8, the Control embryos tended to have higher 
blastocyst rates (p=0.06). When siASH2L embryos were compared with siNULL, no 
significant difference was observed in blastocyst development (31.3% vs 33.3%, respectively 
p>0.2). All embryo groups developed to the blastocyst stage with good morphology and a 
low number of extruded cells, suggesting good quality embryos in each treatment group 
(Figure 3.2).   
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Figure 3.1- Cleavage and blastocyst rates for bovine embryos in the Control, siNULL, and 
siASH2L embryo groups. Data was analyzed with a one-way ANOVA and Tukey HSD, 
alpha was set at 0.05.  
 
 
 
Treatment 
Number 
Cultured 
Number 
Cleaved 
Percent 
Cleaved 
Number 
Blastocyst 
Percent 
Blastocyst 
Control 425 357 84.0 ± 3.2%a 179 42.1 ± 4.7%a 
siNULL 418 347 83.0 ± 4.2%a 139 33.3 ± 1.9%a 
siASH2L 466 404 86.7 ± 1.8%a 146 31.3 ± 2.0%a 
 
Table 3.1 - Embryo development rates ± S.E.M for Control, siNULL, and siASH2L embryo 
groups. Same letter indicates no sirnigicant difference amongst each of the embryo groups. 
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Figure 3.2 – Representative images of blastocysts embryos on Day 8 of development. Bright 
field images were taken for the Control (20X), siNULL (20X), and siASH2L (40X) embryos. 
Fluorescent photos (right image) are shown in the siNULL and siASH2L for visual 
confirmation of microinjection.  
 
 
 
CRISPR-Cas9 Targeting ASH2L 
After three rounds of IVF and microinjections, embryos (N=770) were analyzed for 
cleavage and blastocysts rates between the Control, sgNULL, sgASH2L Target 1, and 
sgASH2L Target 2 embyro groups. Cleavage rates were consistent between all embryo 
Control 
siNULL 
siASH2L 
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groups (Figure 3.3, Table 3.2). Blastocysts rates for the sgNULL, sgASH2L Target 1, and 
sgASH2L Target 2 were all significantly different from the non-injected controls (p=0.02, 
Figure 3.3, Table 3.2). When sgNULL was compared with the sgASH2L Target 1 embryos 
no significant difference in blastocyst development was observed (p=0.12). A significant 
decrease in blastocyst rates was observed between sgNULL and sgASH2L Target 2 group 
(40.3 ± 3.0% vs 31.9 ± 2.1%, respectively, p=0.03). Morphology of blastocyst embryos in  
each treatment groups were of similar stage and quality on Day 8 (Figure 3.4).  
 
Treatment 
Number 
Cultured  
Number 
Cleaved 
Percent 
Cleaved 
Number 
Blastocyst 
Percent 
Blastocyst 
Control 159 144 91.0 ± 1.5%a 79 49.1 ± 3.3%a 
sgNULL 235 202 85.0 ± 3.0%a 94 40.3 ± 3.0%b 
sgASH2L 
Target 1 
185 159 85.0 ± 5.0%a 63 33.6 ± 5.0%bc 
sgASH2L 
Target 2 
191 170 87.0 ± 6.5%a 61 31.9 ± 2.1%c 
Table 3.2 - Embryo development rates ± S.E.M for Control, sgNULL, sgASH2L Target 1 
and sgASH2L Target 2 embryo groups. Values within a column with different superscripts 
are significantly different (p <0.05)  
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Figure 3.3 – Cleavage and blastocyst development rates for bovine embryos for the Control, 
siNULL, and sgASH2L embryo groups. Data was analyzed with a one-way ANOVA and 
Tukey HSD, alpha was set at 0.05. Significant difference between treatment groups is 
represented by a change in letter.  
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Figure 3.4 – Representative images for morphological analysis of blastocyst embryos on Day 
8 of development. Bright field (20X) and flourescent photos (right) are shown in the 
sgNULL, sgASH2L Target 1 and sgASH2L Target 2 for confirmation of being 
microinjected.  
Control 
sgNULL 
sgASH2L 
Target 1 
sgASH2L 
Target 2 
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ASH2L Expression Levels in Bovine Embryos 
 Embryos were examined at the 8-cell and blastocyst stage to see if the siRNAs were 
effective for suppressing ASH2L in the early embryo. Three biological replicates showed 
that the siRNAs targeting ASH2L reduced expression by 98% at the 8-cell stage and 82% at 
the blastocyst stage when compared to the sham-injected controls (P<0.0001, Figure 3.5). 
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Figure 3.5 – ASH2L expression levels at the 8-cell and blastocyst stage in comparison to the 
Control and siNULL embryo groups. Data was analyzed with a one-way ANOVA and Tukey 
HSD, alpha was set at 0.05. Data observed to be significantly different from Control and 
siNULL groups is represented by *.   
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Immunocytochemistry 
Analysis of 5mc and 5hmc 
5mc and 5hmc levels were examined at the blastocyst stage to determine the effects 
of suppression of ASH2L in the early embryo. ICC analysis showed a significant increase in 
global cytosine methylation in the ASH2L suppressed embryo group when compared to the 
Control and siNULL embryos (0.35, 0.26, and 0.30, respectively, P<0.01, Figure 3.6). 
Hydroxymethlyation decreased in siASH2L embryos when matched with the non-injection 
and sham-injected controls (0.75, 0.93,  and 0.87, respectively, P<0.0001,Table 3.3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 – ICC results of 5mc and 5hmc levels in blastocyst stage embryos for Control, 
siNULL, and siASH2L groups. Data was analyzed with a one-way ANOVA and Tukey 
HSD, alpha was set at 0.05. Significant difference between treatment groups is represented 
by a change in letter. 
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Primary 
Antibodies 
Control siNULL siASH2L 
5hmc 0.93 ± .02a 0.87 ± .02b 0.75 ± .01c 
5mc 0.26 ± .01a 0.30 ± .02b 0.35 ± .01c 
H3K4me2 1.61 ± .04a 1.28 ± .10b 1.53 ± .03c 
H3K9me2-3 0.71 ± .01a 0.69 ± .01ab 0.67 ± .01b 
H3K4me3 0.57 ± .02a 0.58 ± 02a 0.48 ± .02b 
H3K27me3 0.53 ± .01a 0.54 ± .02a 0.62 ± .02b 
 
Table 3.3 - ICC results showing fluorescent intensity ratios with S.E.M. of DNA and histone 
methylation at the blastocyst stage of development. Different letters within a row indicate 
significant (p<0.05) difference between the groups. 
 
 
 
Analysis of Posttranslational Histone Modifications 
Blastocyst (N=425) from each treatment group were examined for posttranslational 
histone modifications by ICC. Depletion of ASH2L altered histone methylation levels with 
decreased levels of H3K4me3 (0.48, 0.57, and 0.58, p<.0006) and increased levels of 
H3K27me3 (0.62, 0.53, 0.54 p<.001) present in the siASH2L, Control and siNULL embryos, 
respectively (Figure 3.7, Table 3.3, and Figure 3.8). Depletion of ASH2L in the early embryo 
had no effect on H3K9me2-3 levels at the observed stage of development (p=.16). H3K4me2 
levels were significantly altered due to injection of either the null siRNA or siASH2L, thus 
no meaningful interpretation of these data can be made. This may be due to increased non-
specific fluorescence seen in the H3K4me2 embryos (Figure 3.9). 
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Figure 3.7 – ICC results analyzing histone methylation levels in blastocyst embryos in 
Control, siNULL, and siASH2L groups. Data was analyzed with a one-way ANOVA and 
Tukey HSD, alpha was set at 0.05. Significant difference from Control group is indicated by 
*. Significant difference from the Control and sgNULL group is represented by **.  
 
 
 
 
Figure 3.8 – ICC images of Day 7 blastocyst for the Control, siNULL, and siASH2L groups 
labeled for H3K4me3 and H3K27me3. Embryos stained and labeled images are for 
H3K4me3 (FITC), H3K27me3 (CY3), DNA (DAPI), and a merge of the three images. 
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Figure 3.9 – ICC images of Day 7 blastocyst for the Control, siNULL, and siAHS2L groups 
labeled for H3K4me2 and H3K9me2-3. Embryos stained and labeled images are for 
H3K4me2 (FITC), H3K9me2-3 (CY3), DNA (DAPI), and a merge of the three images. 
 
 
 
Preliminary Data of Targeted Mutations of ASH2L in Embryos  
sgASH2L Target 1 Sequences 
Individual sgASH2L Target 1 blastocysts were randomly selected from three different 
repilicates (N=20)  and sequenced to observe if mutations were present in the ASH2L coding 
sequence. Observation of the targeted portion of the ASH2L gene sequenced showed the dual 
sgRNAs for the Target 1 site was 65% (13/20) effective for altering the ASH2L coding 
sequence (Figure 3.10). From the mutated embryos 69% (9/13) resulted in missense/silent 
mutation that caused no shift in the coding sequence. The remaining four mutated embryos 
resulted in either an in-frame or frameshift mutation. Two embryos were suggested to have a 
biallelic frameshift mutations that would suggest disruption to the ASH2L coding sequence 
for Exon 1. Further sequence analysis of reverse strand is needed to confirm this result.  
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Figure 3.10 – Sequence results from Day 8 embryos targeted with the first site of the 
CRISPR-Cas9 cascade. Green letters represent the PAM sequences for the target sites of the 
sgRNAs. Red letters indicate were the mutations are present with lower case letters 
representing a monoallelic mutation with capital letters representing a biallelic mutation.  
Right column shows change in coding sequence is present with Δ represents a mutation that 
did not result in change to the coding sequence. WT represents that the wild type sequence 
was present. 
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sgASH2L Target 2 Sequences 
Individual blastocyst from the sgASH2L Target 2 group were randomly selected from 
three different repilicates (N=21)  and the targeted portion of the ASH2L gene sequenced to 
examine if mutations were present (Figure 3.11). The overall targeting efficiency for the dual 
guides for the Target 2 site was 48% (10/21). From the ten mutations, seven resulted in what 
is a suggested biallelic frameshift mutations that would suggest by a chromatograph a 
disruption of the coding sequence in Exon 12. Further sequence analysis of the 
complementary strand is needed in order to confirm this preliminary result. The other three 
mutations caused a single nucleotide polymorphism (SNP) that would cause no shift in the 
coding sequence.  
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Figure 3.11 – Sequence results from Day 8 embryos targeted with the second site of the 
CRISPR-Cas9 cascade. Green letters represent the PAM sequences for the target sites of the 
sgRNAs. Red letters indicate were the mutations that are present with lower case letters 
representing a monoallelic mutation with capital letters representing biallelic mutation.  Right 
column show change in coding sequence is present with Δ representing a mutation that did 
not result in change to the coding sequence. WT represents that the wild type sequence was 
present. 
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Day 17 Conceptus Collection Morphology 
 On Day 17, conceptuses were collected from the siNULL and siASH2L transfers 
groups. The overall recovery rate from the siASH2L embryos transferred was 58.3% (7/12), 
while the siNULL recovery rate was 56.3% (9/16).  Conceptuses collected from both 
treatment groups had an intact embryonic disc and also shown to be elongated  at this point 
in developement (Figure 3.12 and 3.13). Variation in size of the filamentous conceptus was 
observed with both treatment groups. 
 
 
  
   
 
Figure 3.12 - Representative images of early elongation Day 17 conceptuses from the 
siNULL (A) and siASH2L (B) collected conceptuses.  Green arrow points to embryonic disc 
that is intact in the preimplanted embryos.  
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Figure 3.13 – Representative images of elongated Day 17 conceptus from the siNULL (A) 
and siASH2L (B) collected conceptuses.  
 
 
 
RNA-Seq Data 
 RNA was collected from  Day 17 conceptuses from the siNULL (N=3) and siASH2L 
(N=4) groups. These conceptuses were analyzed for global transcript profiles by RNA-Seq. 
Embryos of similar morphological appearance were compared with from the siNULL and 
siASH2L embryos during RNA-seq analysis. RNA-seq data showed the suppression of 
ASH2L by siRNA injection of zygotes resulted in altered gene expression profiles on Day 17 
conceptuses (Table 3.4). Genes that were the most significantly altered were examined for 
common cell lineages in the Day 17 conceptus (Table 3.5). The BMP pathway was 
discovered to have significantly altered transcript levels present that originate from 
mesenchymal stem cells present in the Day 17 embryo. 
 
 
 
 
A B 
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Gene Exp. Value Up 
Regulated 
Gene Exp. Value Down 
Regulated 
SLC27A6 7.173 CCL27 -4.636 
ZFP3 6.041 AQP3 -3.709 
FAM213A 2.873 CALB1 -3.453 
PAGE4 2.374 PCK1 -3.245 
GAL3ST2 2.184 GPX2 -3.170 
EEF1A1 1.999 S100A1 -2.893 
ZNF521 1.983 SLC38A5 -2.846 
PKD2L1 1.957 LFITM7 -2.807 
SLC16A9 1.830 VCAN -2.564 
DLX5 1.784 WNT11 -2.563 
 
Table 3.4 – Genes most significantly up and down regulated due to the suppression of 
ASH2L in the Day 17 conceptuses. 
 
 
 
Transcriptional Changes 
in Day 17 Conceptuses 
(siNULL vs siASH2L) 
Upregulated 
Genes 
Down Regulated 
Genes 
109 318 
 
Table 3.5- Number of genes altered in gene expression when compared to siNULL 
conceptuses (p<0.05). 
 
 
 
RNA-Seq Validation 
RNA-seq showed abnormal gene expression patterns present in mesynchymal stem 
cells. The mRNA expression levels of ZFP3, ZNF521, DLX5, CCL27, and WNT11 were 
examined via RT-qPCR in order to validate the RNA-seq expression results. Gene expression 
analysis showed that ZNF521 and DLX5 were significantly increased in siASH2L when 
compared to siNULL conceptuses (P=0.023 and P=0.033, respectively, Figure 3.14). No 
significant difference was observed with ZFP3 (P=0.303). Changes in CCL27 and WNT11 
were not observed in mRNA expression analysis.   
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Figure 3.14 – Relative gene expression of genes associated with the BMP pathways in 
siNULL and siASH2L conceptuses. Data was analyzed with a one-way ANOVA and Tukey 
HSD, alpha was set at 0.05. Data that was observed to be significantly different from 
siNULL group is represented by *.  
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CHAPTER IV 
CONCLUSIONS 
 
Introduction 
 We hypothesized  that depletion or deletion of ASH2L in bovine zygotes would alter 
preimplantation development, epigenetic reprogramming, gene expression, and result in 
morphological differences in the early bovine embryo. Results showed that reduction or 
removal of ASH2L did not inhibit blastocyst development. Further investigation found that 
suppression of ASH2L showed no morphological variation from sham-injected controls on 
Day 17. This result suggests that suppression of ASH2L in the early embryo does not have a 
detrimental effect on development during the preimplantation period. 
We investigated epigenetic modifications in the ASH2L depleted embryos and found 
abnormal DNA and histone methylation patterns were present. Transcriptome analysis of the 
Day 17 conceptuses showed altered gene expression profiles that resulted from suppression 
of  ASH2L in the early embryo. Even though these embryos appeared to be morphologically 
and developmentally competent, chromatin modifications and gene expression on Day 17 
suggest otherwise. These findings propose that reduction of ASH2L during the 
reprogramming period of the embryo would have a detrimental effect later during post-
implantation development.  
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Embryo Development for RNA Interference  
Suppression of ASH2L did not alter cleavage and blastocyst development in the early 
embryo. When comparing these results with other HMTs and DNMTs, ASH2L was the only 
gene studied, when suppressed, did not alter development up to the blastocyst stage [107-
111]. This result in the bovine is comparable to a study in mice that showed ASH2L-null 
embryos were viable at the blastocyst stage [125].  It also suggests that histone modifications 
associated with ASH2L may not play a necessary role during this developmental period.  
With low expression levels of ASH2L present in bovine embryos, it is not an exact 
comparison to the mouse study. The low level of transcripts present suggest that some 
ASH2L protein is being produced in the early embryo. Analysis of ASH2L protein 
expression in the early bovine embryo would be ideal to further validate this assumption. 
However, this is not an option as there are no commercially produced antibodies that 
effectively target bovine ASH2L. To have a more comparable model to the ASH2L-null 
mouse, a knockout of ASH2L in the bovine embryo is needed to see if the technical 
limitations from RNA interference allowed for continuation of development [89].  
 
CRISPR Embryo Development and Sequencing 
To create a bovine model similar to what was previously used in mice, we utilized the 
CRISPR-Cas9 approach to target the bovine ASH2L coding sequence. The preliminary data 
from the sequence analysis comfirmed we were able to create mutations in the coding 
sequence as previously seen in other mammals using CRISPR-Cas9 [89, 129-131]. The 
suggested double strand break caused by Cas9 was repaired by the error prone repair 
mechanism of NHEJ that resulted with InDels being present [132, 133].  A portion of these 
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InDels caused a frameshift mutation thus disrupting the function of the ASH2L protein. 
Embryos with the suggested biallelic frameshift mutations still developed to the blastocyst 
stage, which is comparable to results reported with ASH2L-null mice [123]. Sequence 
analysis of the reverse stand would need to be performed in order to confirm that the double 
strand mutations are present.  
With the sgASH2L Target 1 group, the majority of the sequences had missense or 
silent mutations present, which may not cause a change in protein function. Mutations from 
the sgASH2L Target 2 were advocated to have more biallelic frameshift mutations, but were 
less efficient at targeting the coding sequence. Selection of competent sgRNAs has become 
an increased area of research for increasing the efficiency of CRISPR-Cas9 and is similar to 
that previously seen with RNA interference [134-136]. Since the targeting efficiency for 
CRISPR-Cas9 was not 100% effective, we reverted back to the RNA interference approach 
for the rest of the studies analyzing the role of ASH2L during preimplantation development.  
The sgRNAs used to target site 2 in the ASH2L gene resulted in a small but 
significant reduction in blastocyst development.  The lower blastocyst  rates from the 
sgASH2L Target 2 group can be explained by a couple of different possibilities. One could 
be off-target effects that are sometimes observed with CRISPR-Cas9 studies [137, 138]. It 
has been shown that off-targeting effects can happen with mismatches of up to 5 nucleotides 
upstream of the seed sequence for the sgRNA [139]. The other possibility could be from 
impurities present during preparation of the sgRNAsthat were used for microinjections. Any 
impurity or osmolarity change in the injection buffer could alter development of the early 
embryo.  
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Epigenetic Modifications  
Similar to studies in mice, the suppression of ASH2L in the early embryo resulted in 
a global decrease of H3K4me3 levels in the blastocyst embryos [115]. This suggest that an 
altered gene transcription profile would be present in the ASH2L depleted blastocyst with 
numerous studies showing H3K4me3 having a role on facilitating a transcriptionally 
permissive chromatin status [100, 101]. Abnormal histone methylation patterns were also 
observed with the decease of H3K27me3 levels in the ASH2L suppressed embryo.  
We observed H3K4me2 levels were significantly different from both the Control and 
siNULL embryos at the blastocyst stage. However, these altered levels of H3K4me2 are 
likely caused by problems with nonspecific binding of the primary antibody that leads to 
overstaining of secondary antibody, causing variation in fluorescent intensity levels.  The 
reason for the nonspecific binding may have been due to the blocking buffer not being 
optimized for the primary polyclonal antibody produced in goat verses the other monoclonal 
antibodies utilized in these studies. 
Even with the observed changes in histone methylation, the siASH2L embryos still 
developed comparably to the Control and siNULL embryos. The altered epigenetic status 
shows these changes did not result in embryonic lethality at this point in development. It also 
advocates that H3K4me3 may not play as critical role during the early developmental stages 
of the embryo. A previous study in Drosopila, has showed H3K4me3 levels are higher in 
stably expressed genes when compared to actively expressed genes [140]. This study 
suggests that ASH2L when regulating H3K4me3 levels may not facilitate active gene 
expression patterns as we had previously hypothesized during preimplantation development.  
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Altered DNA methylation patterns were present in ASH2L suppressed and NULL 
injected embryos at the blastocyst stage. This shows that even the micromanipulation 
methods that were utilized reformed the methylation status of the early embryo. With the 
ASH2L suppressed group, it was observed that these abnormal methylation patterns were 
more prevalent in the bovine blastocyst. It has been shown that an increase in DNMT3a was 
present when H3K4me3 was absent in mammalian cells [141]. Previous studies have also 
shown that the Polycomb group can mediate recruitment of DNA methyltransferases by 
regulation of H3K27me3 [142]. The altered histone methylation patterns are thus likely cause 
for the decrease in hydroxymethylation that is present in the ASH2L depleted blastocysts.  
 
Day 17 Embryo Collections 
 Since it was previously observed that suppression of ASH2L did not alter 
development to the blastocysts stage, it would be advantageous to examine siASH2L 
embryos later in development. Previous studies in mice suggest ASH2L suppressed embryos 
would not be viable after the blastocyst stage since ASH2L-null embryos were nonviable 
between the blastocyst stage and mid gestation [123]. Collection of the Day 17 conceptuses 
showed suppression of ASH2L did not inhibit development of the embryonic disc and 
elongation of the conceptus. The ASH2L embryos did have various lengths of filamentous 
conceptuses at this point in development. The altered elongation patterns were present in 
both siNULL and siASH2L conceptus groups thus suggesting it is caused by the maternal 
environment. It has been shown when high levels of progesterone are present in the maternal 
uterine environment, elongation of conceptus occurs more rapidly when compared to lower 
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levels [143, 144]. These findings show that the suppression of ASH2L did not alter 
morphological development of the conceptus before binding to the uterine epithelium.  
 
RNA-Seq and Validation  
As we hypothesized, abnormal gene expression profiles were present in the Day 17 
conceptus due to the suppression of ASH2L in the early embryo. The most significantly up 
and down regulated RNA-seq data showed abnormal transcripts were present in the BMP and 
TGF-beta pathways that arise from mesenchymal stem cells present in the Day 17 conceptus 
[145]. This was validated by RT-qPCR, that showed abnormal gene expression patterns were 
higher, when compared to control group, for ZNF521 and DLX5. The altered mRNA 
expression levels for these genes were consistent with the RNA-seq data. When these 
messenchymal stem cells begin to differention they form osteocytes, chondrocyts, that are 
responsible for making cartilage and bone [146, 147]. To see if this would has an effect on 
pregnancy, embryos depleted of ASH2L in the early embryo would need to develop past Day 
17 conceptus. ZNF521 and DLX5 have also been shown to be expressed in trophoblastic 
cells that form into the placenta [148]. DLX5 is also a maternally expressed gene that has 
been shown to be abnormally methylated and mRNA expression upregulated in preclamptic 
placentas of humans [149, 150]. The effect of overexpression of DLX5 in the bovine placenta 
has yet to be studied. No effect was observed with other imprinting genes due to the 
suppression of ASH2L in the Day 17 conceptus.  
No change in gene expression was observed in RNA-seq validation of ZFP3, CCL27, 
and WNT11. In control embryos, expression levels were examined in comparison to 
reference genes (Figure A9). This showed lower expression levels were present in the genes 
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than those that were validated by RT-qPCR. It has been shown that RNA-seq is more 
sensitive and can detect low level transcripts [151]. This shows that the altered transcriptome 
profile that was observed with RNA-seq not have as wide spread outcome as previously 
thought.  
It was previously shown that ASH2L played a role in HOX gene expression by 
increasing the trimethylation of H3K4me3 [118, 119]. Altered histone methylation patterns 
of H3K27me3 and H3K4me3 were present in blastocysts suppressed for ASH2L and was 
suggested to have an inhibitory effect on HOX gene expression during embryonic 
development.  Studies have shown H3K27me3, via the PcG, and H3K4me3, by way of TrxG, 
are associated with HOX gene expression of the early embryo [152, 153]. This change in 
HOX gene expression suggests that phenotypic abnormalities would be present later in 
development [154]. However, we did not observe drastic alterations in HOX gene expression 
patterns were present in the Day 17 conceptus. Studies in mice have showed that HOX gene 
expression was higher in mid gestation (Day 10.5-16.5) [155]. These findings in mice would 
suggest that HOX gene expression would be more prevalent later in development.   
 
Summary 
 To characterize the role of ASH2L, we examined whether depletion or deletion of 
ASH2L would alter preimplantation development, embryo morphology, epigenetic 
reprogramming, and gene expression. Developmental data showed the suppression or 
deletion of ASH2L in the early embryo did not affect the developmental potential to the 
blastocyst stage during in vitro development. Embryos from both studies had morphology 
that suggested good quality blastocysts in accordance to IETS guidelines. Furthermore, the 
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ASH2L suppressed embryos continued development throughout preimplantation and on Day 
17 no morphological variances were observed when compared to respective controls.  
 More in depth analysis of ASH2L depleted embryos showed abnormal distribution of 
cytosine and histone methylation patterns at the blastocyst stage. This altered epigenetic state 
suggested a chromatin status that does not facilitate transcription and would alter gene 
expression later in development. It also questions the role of H3K4me3 in the early embryo 
due to the decrease levels present in the ASH2L suppressed embryos. Transcriptome analysis 
of ASH2L suppressed conceptuses showed altered gene transcriptome profiles were present 
that are associated with mesenchymal stem cells on Day 17. These findings suggest that the 
suppression of ASH2L in the early embryo altered gene expression associated with stem cells 
and this could have an effect later during post-implantation development. These findings 
show alteration to normal ASH2L levels in the early embryo could be a link to inferior 
embryos that arise from IVP.  
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APPENDIX 
Sense Strand        5’ – CACCGNNNNNNNNNNNNNNNNNNNN  – 3’ 
Antisense Stand   3’ –            CNNNNNNNNNNNNNNNNNNNNCAAA   – 5’  
Figure A1 – Design of sgRNA to allow for insertion of oligonucleotides into the previously 
linearized Bbs1 linearized PX459-Puro plasmid. 
 
 
 
               
 
Figure A2 - Gel image for double digest with EcoRV and Bbs1. Left lane are undigested 
Miniprep of the inserted plasmid, middle lane is EcoRV digested, and right lane is double 
digested with EcoRV and Bbs1. 
 
 
 
PX459 ASH2L Target 1 
AAAGGACGAAACACCGAGAAGAAGGGGAGACGAAGCGTTTTAGAGCTAGAAAT 
 
PX459 ASH2L Target 2 
AAAGGACGAAACACCGTTAGCAGCTGCTGCCGGGCCGTTTTAGAGCTAGAAATA 
 
PX459 ASH2L Target 3 
AAAGGACGAAACACCGAAACACTACTCTTCTGGCTAGTTTTAGAGCTAGAAATA 
 
PX459 ASH2L Target 4 
AAAGGACGAAACACCGAGTAGTGTTTGCCAATGGACGTTTTAGAGCTAGAAATA 
 
Figure A3 – Sequence results from plasmid DNA with inserted sgRNA sequences for 
targeting ASH2L gene. Underlined green letters indicate the target sequence to be inserted 
into the plasmid. 
PX459 1F PX459 2F PX459 2R PX459 1R 
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Figure A4 – Image of positive control transfected cell at 36 hours post transfection. Cells 
were transfected with the plasmid PX458 (GFP) in bovine fibroblasts with BF (Image A) and 
FITC (Image B). Transfection efficiency was an overall 30-35% in positive control wells. 
 
 
 
Component Reaction Volume 
10X Buffer 2.5 µl 
dNTPs 0.5 µl 
ASH2L Target 1 or 2 Forward 
Primer 
0.5 µl 
ASH2L Target 1 or 2 Reverse 
Primer 
0.5 µl 
MgCl2 0.75 µl 
DNA/RNase Free Water 16.125 µl 
Taq Polymerase .125 µl 
Total Volume 21.0 µl 
Table A1 – PCR components for amplification of the ASH2L targeted regions.  
 
 
A B 
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Step Temperature Time Cycles 
1 95ºC 30 seconds 1 
2 95ºC 15 seconds 40 
3 60ºC 30 seconds 40 
4 68ºC 1 minute 40 
5 68ºC 5 minutes 1 
6 4ºC Forever 1 
 
Table A2 – Thermocycler conditions for running reactions for the embryos targeted with 
ASH2L Target 1 sgRNAs. 
 
 
 
Step Temperature Time Cycles 
1 95ºC 30 seconds 1 
2 95ºC 15 seconds 40 
3 57ºC 30 seconds 40 
4 68ºC 1 minute 40 
5 68ºC 5 minutes 1 
6 4ºC Forever 1 
 
Table A3 – Thermocycler conditions for running reactions for the embryos targeted with 
ASH2L Target 2 sgRNAs. 
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sgASH2L Guide 1 Sequence  
ACCGGCAGAAGAAGGGGAGACGAATCAGGCAGCAGCCGTAGCGGC       119 T-G 
sgASH2L Guide 2 Sequence  
AGTGAGCGCAGGACCCGGCCCGGCAGCTGCTGCTAATGCAACACCG          49 A-C 
sgASH2L Guide 3 Sequence  
TTCTGGCAAACACTACTCTTCTGGCTATGGACAGGGAGACGTCCTG         1443 C-T 
sgASH2L Guide 4 Sequence 
TTCTGGCTACGGACAGGGAGACGTCCTGGAAATTTTATATCAACCT         1463 G-A 
 
Figure A5 – Sequences from bovine fibroblast cells transfected with CRISPR plasmids 
targeting the coding sequence of ASH2L. PAM sequences are underlined in order to show 
the target site of the plasmid. The sgASH2L Guide 2 sequence from the antisense strand so 
the PAM site is represented as CCN. 
 
 
 
 
Figure A6 – Chromatograph from an embryo that represents a monoallelic mutation in the 
coding sequence. The PAM target sequence is underlined to indicate the target site of the 
CRISPR-Cas9 Complex. 
1463x AA 
56 T-A 
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 Figure A7 – Chromatograph of a sequence with a biallelic mutation in the coding sequence.  
 
 
 
T7 Forward Primer- TTAATACGACTCACTATAGGCTTTATATATCTTAGTAG 
T7 Reverse Primer – AAAAGCACCGACTCGGTGCC 
Figure A8 – Primers used for the insertion of the T7 promoter and amplification of the 
sgRNA sequence. The underlined portion of the forward primer is the T7 promoter sequence 
needed for T7 MEGASCRIPT Kit (Ambion).  
 
Step Temperature Time Cycles 
1 98ºC 30 seconds 1 
2 98ºC 10 seconds 35 
3 55ºC 15 seconds 35 
4 72ºC 5 seconds 35 
5 72ºC 5 minutes 1 
6 4ºC Forever 1 
 
Table A4 – PCR conditions for insertion of the T7 promoter and amplification of the target 
sequence. 
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Figure A9 – Relative expression levels of gene expression in the Day 17 conceptuses of the 
siNULL embryo group when compared to the reference genes.  
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